Trial · NCT03018249
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score) | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | 53.6 | Standard Deviation 64.8 | units on a scale | |
| Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score) | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | 42.7 | Standard Deviation 49.0 | units on a scale | |
| Percentage of Participants With a Histologic Response | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | 16 | Participants | ||
| Percentage of Participants With a Histologic Response | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | 14 | Participants | ||
| Percent of Participants With a Ki67 Response | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | 15 | Participants | ||
| Percent of Participants With a Ki67 Response | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | 18 | Participants | ||
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | Grade 1 AE | 11 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | Grade 1 AE | 9 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | Grade 2 AE | 4 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | Grade 2 AE | 6 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | Grade 3 AE | 2 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | Grade 3 AE | 2 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | Grade 4 AE | 0 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | Grade 4 AE | 0 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | Grade 5 AE | 0 | participants | |
| The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE) | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | Grade 5 AE | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03018249/results